CN113396147A - 芳香杂环类衍生物调节剂、其制备方法和应用 - Google Patents
芳香杂环类衍生物调节剂、其制备方法和应用 Download PDFInfo
- Publication number
- CN113396147A CN113396147A CN202080012821.0A CN202080012821A CN113396147A CN 113396147 A CN113396147 A CN 113396147A CN 202080012821 A CN202080012821 A CN 202080012821A CN 113396147 A CN113396147 A CN 113396147A
- Authority
- CN
- China
- Prior art keywords
- radical
- alkyl
- amino
- cyano
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title abstract description 143
- 125000006615 aromatic heterocyclic group Chemical group 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- 125000001424 substituent group Chemical group 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 6
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 6
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000032839 leukemia Diseases 0.000 claims abstract description 5
- 201000001441 melanoma Diseases 0.000 claims abstract description 5
- -1 amino, hydroxy Chemical group 0.000 claims description 358
- 125000000623 heterocyclic group Chemical group 0.000 claims description 215
- 125000000217 alkyl group Chemical group 0.000 claims description 193
- 229910052739 hydrogen Inorganic materials 0.000 claims description 154
- 239000001257 hydrogen Substances 0.000 claims description 154
- 150000003254 radicals Chemical class 0.000 claims description 146
- 150000002431 hydrogen Chemical class 0.000 claims description 143
- 229910052736 halogen Inorganic materials 0.000 claims description 140
- 150000002367 halogens Chemical class 0.000 claims description 140
- 125000001072 heteroaryl group Chemical group 0.000 claims description 135
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 114
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 97
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 79
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 74
- 229910052805 deuterium Inorganic materials 0.000 claims description 74
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 73
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 72
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 70
- 125000003545 alkoxy group Chemical group 0.000 claims description 66
- 125000003118 aryl group Chemical group 0.000 claims description 65
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 61
- 125000003342 alkenyl group Chemical group 0.000 claims description 54
- 239000000460 chlorine Substances 0.000 claims description 52
- 125000000304 alkynyl group Chemical group 0.000 claims description 49
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 44
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 38
- 125000001188 haloalkyl group Chemical group 0.000 claims description 38
- 125000005843 halogen group Chemical group 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 37
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 36
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 36
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 33
- 125000004043 oxo group Chemical group O=* 0.000 claims description 33
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 21
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 20
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000005605 benzo group Chemical group 0.000 claims description 12
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 12
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 239000011737 fluorine Substances 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 229940125399 kras g12c inhibitor Drugs 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 4
- 206010029748 Noonan syndrome Diseases 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 2
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims description 2
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims description 2
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 230000035772 mutation Effects 0.000 abstract description 8
- 102200006538 rs121913530 Human genes 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 251
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 219
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 180
- 238000004587 chromatography analysis Methods 0.000 description 178
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 97
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 77
- 235000019439 ethyl acetate Nutrition 0.000 description 77
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 73
- 239000000243 solution Substances 0.000 description 71
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 65
- 239000012044 organic layer Substances 0.000 description 65
- 238000004440 column chromatography Methods 0.000 description 63
- 239000000047 product Substances 0.000 description 58
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 239000012043 crude product Substances 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 47
- 238000001035 drying Methods 0.000 description 45
- 238000003756 stirring Methods 0.000 description 37
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- 238000001914 filtration Methods 0.000 description 27
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 238000000746 purification Methods 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 20
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 19
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 19
- 239000003480 eluent Substances 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 238000010791 quenching Methods 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 235000019270 ammonium chloride Nutrition 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 125000006413 ring segment Chemical group 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 12
- 239000003208 petroleum Substances 0.000 description 12
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 12
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 12
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 11
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 125000003367 polycyclic group Chemical group 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 125000003282 alkyl amino group Chemical group 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 125000000000 cycloalkoxy group Chemical group 0.000 description 10
- 125000005366 cycloalkylthio group Chemical group 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000007942 carboxylates Chemical class 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229910000104 sodium hydride Inorganic materials 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- UUNIOFWUJYBVGQ-UHFFFAOYSA-N 2-amino-4-(3,4-dimethoxyphenyl)-10-fluoro-4,5,6,7-tetrahydrobenzo[1,2]cyclohepta[6,7-d]pyran-3-carbonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C1C(C#N)=C(N)OC2=C1CCCC1=CC=C(F)C=C12 UUNIOFWUJYBVGQ-UHFFFAOYSA-N 0.000 description 7
- OXJTVPMAMRSGNT-UHFFFAOYSA-N 7-chloro-6-fluoro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4-dione Chemical compound ClC=1C(=CC2=C(N(C(NC2=O)=O)C=2C(=NC=CC=2C)C(C)C)N=1)F OXJTVPMAMRSGNT-UHFFFAOYSA-N 0.000 description 7
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 6
- FPXQHZPCFRQWCP-UHFFFAOYSA-N (2-fluoro-6-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=C(O)C=CC=C1F FPXQHZPCFRQWCP-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100030708 GTPase KRas Human genes 0.000 description 6
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 235000010290 biphenyl Nutrition 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Substances ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- VXPOAPWLMVAUCK-UHFFFAOYSA-N 4-methyl-2-propan-2-ylpyridin-3-amine Chemical compound C(C)(C)C1=NC=CC(=C1N)C VXPOAPWLMVAUCK-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 description 5
- 102000016914 ras Proteins Human genes 0.000 description 5
- 108010014186 ras Proteins Proteins 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- FMLPQHJYUZTHQS-QMMMGPOBSA-N tert-butyl (3s)-3-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-QMMMGPOBSA-N 0.000 description 5
- 238000004293 19F NMR spectroscopy Methods 0.000 description 4
- CIRDRIRDUYTSBM-UHFFFAOYSA-N 4,7-dichloro-6-fluoro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2-one Chemical compound ClC=1C2=C(N(C(N=1)=O)C=1C(=NC=CC=1C)C(C)C)N=C(C(=C2)F)Cl CIRDRIRDUYTSBM-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- WAVCNGYXVAVBMI-UHFFFAOYSA-N C=CC(=O)N1CCN(CC1)C(=O)C2=CC(=C(C(=C2N)F)Br)Cl Chemical compound C=CC(=O)N1CCN(CC1)C(=O)C2=CC(=C(C(=C2N)F)Br)Cl WAVCNGYXVAVBMI-UHFFFAOYSA-N 0.000 description 4
- SCCUQFRPLRZQNM-UHFFFAOYSA-N CNC1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)Br)F Chemical compound CNC1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)Br)F SCCUQFRPLRZQNM-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 4
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VCOJPHPOVDIRJK-LURJTMIESA-N [(2s)-1-methylpyrrolidin-2-yl]methanol Chemical compound CN1CCC[C@H]1CO VCOJPHPOVDIRJK-LURJTMIESA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XOVMDVZAWWQSDC-UHFFFAOYSA-N (2-fluoro-6-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(F)=C1B(O)O XOVMDVZAWWQSDC-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
- OOQALLDXGQBTTG-UHFFFAOYSA-N 2,6-dichloro-5-fluoro-N-[(4-methyl-2-propan-2-ylpyridin-3-yl)carbamoyl]pyridine-3-carboxamide Chemical compound ClC1=C(C(=O)NC(NC=2C(=NC=CC=2C)C(C)C)=O)C=C(C(=N1)Cl)F OOQALLDXGQBTTG-UHFFFAOYSA-N 0.000 description 3
- ZVYNUGSPFZCYEV-UHFFFAOYSA-N 2,6-dichloro-5-fluoropyridine-3-carboxamide Chemical compound NC(=O)C1=CC(F)=C(Cl)N=C1Cl ZVYNUGSPFZCYEV-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- HDKYIPMDJJVHHA-UHFFFAOYSA-N 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid Chemical compound Nc1c(F)c(Br)c(Cl)cc1C(O)=O HDKYIPMDJJVHHA-UHFFFAOYSA-N 0.000 description 3
- YZCKBXBAFDVMOV-FQEVSTJZSA-N 7-(2-fluoro-6-methoxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[4,3-d]pyrimidin-2-one Chemical compound C[C@H]1CN(CCN1C2=NC(=O)N(C3=CC(=NC=C32)C4=C(C=CC=C4F)OC)C5=C(C=CN=C5C(C)C)C)C(=O)C=C YZCKBXBAFDVMOV-FQEVSTJZSA-N 0.000 description 3
- VPTVZIWEMIDXGX-UHFFFAOYSA-N 8h-quinoline-5,7-dione Chemical compound C1=CN=C2CC(=O)CC(=O)C2=C1 VPTVZIWEMIDXGX-UHFFFAOYSA-N 0.000 description 3
- XFTJNMWGLIRJMS-UHFFFAOYSA-N C1CN(CCN1)C(=O)C2=CC(=C(C(=C2N)F)Br)Cl Chemical compound C1CN(CCN1)C(=O)C2=CC(=C(C(=C2N)F)Br)Cl XFTJNMWGLIRJMS-UHFFFAOYSA-N 0.000 description 3
- YKMSQKTYIGPOQH-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CC(C1)N2CCC(C2=C=O)C(=O)O Chemical compound CC(C)(C)OC(=O)N1CC(C1)N2CCC(C2=C=O)C(=O)O YKMSQKTYIGPOQH-UHFFFAOYSA-N 0.000 description 3
- PBGBUODEJOCHGD-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN2C(C1)CCC(C2=C=O)C(=O)O Chemical compound CC(C)(C)OC(=O)N1CCN2C(C1)CCC(C2=C=O)C(=O)O PBGBUODEJOCHGD-UHFFFAOYSA-N 0.000 description 3
- JLOWBGSRFFNQCT-SFHVURJKSA-N CC(C)C1=NC=CC(C)=C1NC(N=C(C(F)=C1)C(C(O)=CC=C2)=C2F)=C1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=O Chemical compound CC(C)C1=NC=CC(C)=C1NC(N=C(C(F)=C1)C(C(O)=CC=C2)=C2F)=C1C(N(CC1)[C@@H](C)CN1C(C=C)=O)=O JLOWBGSRFFNQCT-SFHVURJKSA-N 0.000 description 3
- BYOVEJKPUPZSDE-UHFFFAOYSA-N CC1=C(C(=NC=C1)C(C)C)N2C3=CC(=NC=C3C(=O)NC2=O)Cl Chemical compound CC1=C(C(=NC=C1)C(C)C)N2C3=CC(=NC=C3C(=O)NC2=O)Cl BYOVEJKPUPZSDE-UHFFFAOYSA-N 0.000 description 3
- NFRWOOOZSIZDJJ-UHFFFAOYSA-N CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CC(C4)N5CCC(=C)C5=C=O)F)C6=C(C=CC=C6F)O Chemical compound CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CC(C4)N5CCC(=C)C5=C=O)F)C6=C(C=CC=C6F)O NFRWOOOZSIZDJJ-UHFFFAOYSA-N 0.000 description 3
- ZRXKECJWSUBOPY-UHFFFAOYSA-N CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CC(C4)N5CCC(=C)C5=C=O)F)Cl Chemical compound CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CC(C4)N5CCC(=C)C5=C=O)F)Cl ZRXKECJWSUBOPY-UHFFFAOYSA-N 0.000 description 3
- JESABZXRLHNSPX-UHFFFAOYSA-N CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCC5(CC4)CC=CC5=C=O)F)C6=C(C=CC=C6F)O Chemical compound CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCC5(CC4)CC=CC5=C=O)F)C6=C(C=CC=C6F)O JESABZXRLHNSPX-UHFFFAOYSA-N 0.000 description 3
- PMICSALADWSGCT-UHFFFAOYSA-N CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCC5(CC4)CC=CC5=C=O)F)Cl Chemical compound CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCC5(CC4)CC=CC5=C=O)F)Cl PMICSALADWSGCT-UHFFFAOYSA-N 0.000 description 3
- MMFFJWRHYUMZPP-UHFFFAOYSA-N CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCN5C(C4)CCC(=C)C5=C=O)F)C6=C(C=CC=C6F)O Chemical compound CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCN5C(C4)CCC(=C)C5=C=O)F)C6=C(C=CC=C6F)O MMFFJWRHYUMZPP-UHFFFAOYSA-N 0.000 description 3
- HNHIWGMKYJAOOO-UHFFFAOYSA-N CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCN5C(C4)CCC(=C)C5=C=O)F)Cl Chemical compound CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCN5C(C4)CCC(=C)C5=C=O)F)Cl HNHIWGMKYJAOOO-UHFFFAOYSA-N 0.000 description 3
- GLXGFCBAJBWFMO-AWEZNQCLSA-N CC1=C(N=C(N=C1Br)OC[C@@H]2CCCN2C)N3CCN(CC3)C(=O)C=C Chemical compound CC1=C(N=C(N=C1Br)OC[C@@H]2CCCN2C)N3CCN(CC3)C(=O)C=C GLXGFCBAJBWFMO-AWEZNQCLSA-N 0.000 description 3
- HWBLDRYKAZSYQP-QFIPXVFZSA-N CC1=C(N=C(N=C1N2CCN(CC2)C(=O)C=C)OC[C@@H]3CCCN3C)C4=CC5=C(C=CC=C5O)C=C4 Chemical compound CC1=C(N=C(N=C1N2CCN(CC2)C(=O)C=C)OC[C@@H]3CCCN3C)C4=CC5=C(C=CC=C5O)C=C4 HWBLDRYKAZSYQP-QFIPXVFZSA-N 0.000 description 3
- ZUPJLFIVKJVOFL-UHFFFAOYSA-N CCOC(=O)C1CCN(C1=C=O)C2CN(C2)C(=O)OC(C)(C)C Chemical compound CCOC(=O)C1CCN(C1=C=O)C2CN(C2)C(=O)OC(C)(C)C ZUPJLFIVKJVOFL-UHFFFAOYSA-N 0.000 description 3
- GPVZJHHQKVIYLG-UHFFFAOYSA-N CN1CC2=C(CC1C3=C(C=CC=C3F)OC)N=C(N=C2N4CCNCC4)OC Chemical compound CN1CC2=C(CC1C3=C(C=CC=C3F)OC)N=C(N=C2N4CCNCC4)OC GPVZJHHQKVIYLG-UHFFFAOYSA-N 0.000 description 3
- QPLVWHOAPWOYQM-HXBUSHRASA-N CN1CCC[C@H]1COC2=NC3=C(CN(C(C3)C4=C(C=CC=C4F)O)C)C(=N2)N5CCN(CC5)C(=O)C=C Chemical compound CN1CCC[C@H]1COC2=NC3=C(CN(C(C3)C4=C(C=CC=C4F)O)C)C(=N2)N5CCN(CC5)C(=O)C=C QPLVWHOAPWOYQM-HXBUSHRASA-N 0.000 description 3
- OWDXYXZBWMGUTH-PBVYKCSPSA-N CN1CCC[C@H]1COC2=NC3=C(CN(C(C3)C4=C(C=CC=C4F)OC)C)C(=N2)N5CCNCC5 Chemical compound CN1CCC[C@H]1COC2=NC3=C(CN(C(C3)C4=C(C=CC=C4F)OC)C)C(=N2)N5CCNCC5 OWDXYXZBWMGUTH-PBVYKCSPSA-N 0.000 description 3
- RDVBGCWZEHMTOL-INHVJJQHSA-N C[C@@H]1CN(C(CN1C(=O)OC(C)(C)C)C(=O)OC)C(=O)C2=CC(=C(C=C2F)Br)F Chemical compound C[C@@H]1CN(C(CN1C(=O)OC(C)(C)C)C(=O)OC)C(=O)C2=CC(=C(C=C2F)Br)F RDVBGCWZEHMTOL-INHVJJQHSA-N 0.000 description 3
- QWIRCEDMWUUXPG-VIFPVBQESA-N C[C@H]1CN(CCN1C(=O)C2=CC(=C(N=C2Cl)Cl)F)C(=O)OC(C)(C)C Chemical compound C[C@H]1CN(CCN1C(=O)C2=CC(=C(N=C2Cl)Cl)F)C(=O)OC(C)(C)C QWIRCEDMWUUXPG-VIFPVBQESA-N 0.000 description 3
- YHSVVZDINGBVGX-SFHVURJKSA-N C[C@H]1CN(CCN1C2=NC(=C=O)N(C3=CC(=NC=C32)Cl)C4=C(C=CN=C4C(C)C)C)C(=O)OC(C)(C)C Chemical compound C[C@H]1CN(CCN1C2=NC(=C=O)N(C3=CC(=NC=C32)Cl)C4=C(C=CN=C4C(C)C)C)C(=O)OC(C)(C)C YHSVVZDINGBVGX-SFHVURJKSA-N 0.000 description 3
- JCRXIWVKEDXWFV-KBPBESRZSA-N C[C@H]1CN(CCN1C2=NC(=NC(=C2)C(=O)O)OC[C@@H]3CCCN3C)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C2=NC(=NC(=C2)C(=O)O)OC[C@@H]3CCCN3C)C(=O)C=C JCRXIWVKEDXWFV-KBPBESRZSA-N 0.000 description 3
- QFOFUYLAYFJENK-JTQLQIEISA-N C[C@H]1CN(CCN1C2=NC(=NC(=C2)C(=O)OC)Cl)C(=O)OC(C)(C)C Chemical compound C[C@H]1CN(CCN1C2=NC(=NC(=C2)C(=O)OC)Cl)C(=O)OC(C)(C)C QFOFUYLAYFJENK-JTQLQIEISA-N 0.000 description 3
- OTGFEZGQRALAPX-QHELBMECSA-N C[C@H]1CN(CCN1C2=NC(=O)N(C3=C2CN(C(C3)C4=C(C=CC=C4F)O)C)C5=C(C=CN=C5C(C)C)C)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C2=NC(=O)N(C3=C2CN(C(C3)C4=C(C=CC=C4F)O)C)C5=C(C=CN=C5C(C)C)C)C(=O)C=C OTGFEZGQRALAPX-QHELBMECSA-N 0.000 description 3
- OPTUVIKJXZVFIR-INIZCTEOSA-N C[C@H]1CN(CCN1C2=NC(=O)N(C3=CC(=NC=C32)Cl)C4=C(C=CN=C4C(C)C)C)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C2=NC(=O)N(C3=CC(=NC=C32)Cl)C4=C(C=CN=C4C(C)C)C)C(=O)C=C OPTUVIKJXZVFIR-INIZCTEOSA-N 0.000 description 3
- MDTSNGMWSVDEOV-SFHVURJKSA-N C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)SC4=C(N=CC=C4)C(F)(F)F)C5=C(C=CN=C5C(C)C)C)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)SC4=C(N=CC=C4)C(F)(F)F)C5=C(C=CN=C5C(C)C)C)C(=O)C=C MDTSNGMWSVDEOV-SFHVURJKSA-N 0.000 description 3
- SWGUBGDCFHYPQQ-INIZCTEOSA-N C[C@H]1CNCCN1C(=O)C2=CC(=C(N=C2NC3=C(C=CN=C3C(C)C)C)C4=C(C=CC=C4F)O)F Chemical compound C[C@H]1CNCCN1C(=O)C2=CC(=C(N=C2NC3=C(C=CN=C3C(C)C)C)C4=C(C=CC=C4F)O)F SWGUBGDCFHYPQQ-INIZCTEOSA-N 0.000 description 3
- XWGOWIMKBASFJP-RYUDHWBXSA-N C[C@H]1CNCCN1C2=NC(=NC(=C2)C(=O)O)OC[C@@H]3CCCN3C Chemical compound C[C@H]1CNCCN1C2=NC(=NC(=C2)C(=O)O)OC[C@@H]3CCCN3C XWGOWIMKBASFJP-RYUDHWBXSA-N 0.000 description 3
- SHANETPSMUIPQV-INIZCTEOSA-N C[C@H]1CNCCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)SC4=C(N=CC=C4)C(F)(F)F)C5=C(C=CN=C5C(C)C)C Chemical compound C[C@H]1CNCCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)SC4=C(N=CC=C4)C(F)(F)F)C5=C(C=CN=C5C(C)C)C SHANETPSMUIPQV-INIZCTEOSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100039788 GTPase NRas Human genes 0.000 description 3
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 238000004237 preparative chromatography Methods 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- GTOSQTHRZIIFOG-UHFFFAOYSA-N tert-butyl 4-(2-chloro-5-methylpyrimidin-4-yl)piperazine-1-carboxylate Chemical compound CC1=CN=C(Cl)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 GTOSQTHRZIIFOG-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- UIOAYOIJMYMOEU-UHFFFAOYSA-N 2-fluoro-6-methoxybenzaldehyde Chemical compound COC1=CC=CC(F)=C1C=O UIOAYOIJMYMOEU-UHFFFAOYSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- YYFLDZZDOUDZQM-UHFFFAOYSA-N 3-[1-[[4-(3-phenylquinolin-2-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 YYFLDZZDOUDZQM-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- YWZSTHLOAZTDFJ-UHFFFAOYSA-N 4-bromo-2,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=C(Br)C=C1F YWZSTHLOAZTDFJ-UHFFFAOYSA-N 0.000 description 2
- IQTHCDAGRCAFJT-UHFFFAOYSA-N 4-methyl-2-propan-2-ylpyridine Chemical compound CC(C)C1=CC(C)=CC=N1 IQTHCDAGRCAFJT-UHFFFAOYSA-N 0.000 description 2
- LQHYRLRJMHMCGG-UHFFFAOYSA-N 8-azaspiro[4.5]dec-2-en-4-one Chemical compound O=C1C=CCC11CCNCC1 LQHYRLRJMHMCGG-UHFFFAOYSA-N 0.000 description 2
- BMYLNWKIHCJFRN-SFHVURJKSA-N 8-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[4,3-d]pyrimidin-2-one Chemical compound C(C=C)(=O)N1C[C@@H](N(CC1)C=1C2=C(N(C(N=1)=O)C=1C(=NC=CC=1C)C(C)C)C(=C(N=C2)C1=C(C=CC=C1O)F)F)C BMYLNWKIHCJFRN-SFHVURJKSA-N 0.000 description 2
- ZOJIZHPUFAXMFQ-IBGZPJMESA-N C(C=C)(=O)N1C[C@@H](N(CC1)C=1C2=C(N(C(N=1)=O)C=1C(=NC=CC=1C)C(C)C)C=C(N=C2)C1=C(C=CC=C1O)F)C Chemical compound C(C=C)(=O)N1C[C@@H](N(CC1)C=1C2=C(N(C(N=1)=O)C=1C(=NC=CC=1C)C(C)C)C=C(N=C2)C1=C(C=CC=C1O)F)C ZOJIZHPUFAXMFQ-IBGZPJMESA-N 0.000 description 2
- WKRNTAOPIPVOLS-UHFFFAOYSA-N C=C1CCC2CNCCN2C1=O.Cl Chemical compound C=C1CCC2CNCCN2C1=O.Cl WKRNTAOPIPVOLS-UHFFFAOYSA-N 0.000 description 2
- VGXVXVINMCPLMU-UHFFFAOYSA-N CC(C)(C)C1=CCC(CC2)(CCN2C(O)=O)C1=C=O Chemical class CC(C)(C)C1=CCC(CC2)(CCN2C(O)=O)C1=C=O VGXVXVINMCPLMU-UHFFFAOYSA-N 0.000 description 2
- ATOUUQCTSFIRJO-SFHVURJKSA-N CC(C)C1=NC=CC(C)=C1N(C(C(C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=C1N)=C2)=CC(Br)=C2F)C1=C=O Chemical compound CC(C)C1=NC=CC(C)=C1N(C(C(C(N(CC1)[C@@H](C)CN1C(OC(C)(C)C)=O)=C1N)=C2)=CC(Br)=C2F)C1=C=O ATOUUQCTSFIRJO-SFHVURJKSA-N 0.000 description 2
- AHJLRTAIQUFHRJ-FKSKYRLFSA-N CC(C)C1=NC=CC(C)=C1N(C(C[N+]([O-])=O)=O)C(C=C(C(F)=C1)Br)=C1C(N(C[C@@H](C)N(C1)C(OC(C)(C)C)=O)C1C(OC)=O)=O Chemical compound CC(C)C1=NC=CC(C)=C1N(C(C[N+]([O-])=O)=O)C(C=C(C(F)=C1)Br)=C1C(N(C[C@@H](C)N(C1)C(OC(C)(C)C)=O)C1C(OC)=O)=O AHJLRTAIQUFHRJ-FKSKYRLFSA-N 0.000 description 2
- MRTXMIVJFLFRIT-UHFFFAOYSA-N CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCC5(CC4)CC(=C)C(=C=O)N5C)F)C6=C(C=CC=C6F)O Chemical compound CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=NC2=O)N4CCC5(CC4)CC(=C)C(=C=O)N5C)F)C6=C(C=CC=C6F)O MRTXMIVJFLFRIT-UHFFFAOYSA-N 0.000 description 2
- NQTAWDRCXPDSPY-LBPRGKRZSA-N CC1=C(N=C(N=C1Br)OC[C@@H]2CCCN2C)N3CCNCC3 Chemical compound CC1=C(N=C(N=C1Br)OC[C@@H]2CCCN2C)N3CCNCC3 NQTAWDRCXPDSPY-LBPRGKRZSA-N 0.000 description 2
- XOYYLSJQEVCZAT-UHFFFAOYSA-N CN(C)C1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)Br)F Chemical compound CN(C)C1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)Br)F XOYYLSJQEVCZAT-UHFFFAOYSA-N 0.000 description 2
- NUONXFPXYILRBY-UHFFFAOYSA-N CN(C)C1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)C3=C(C=CC=C3F)O)F Chemical compound CN(C)C1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)C3=C(C=CC=C3F)O)F NUONXFPXYILRBY-UHFFFAOYSA-N 0.000 description 2
- MPFFDQYFXIXPOY-HSTJUUNISA-N CN1CCC[C@H]1COC2=NC3=C(CN(C(C3)C4=C(C=CC=C4F)OC)C)C(=N2)N5CCN(CC5)C(=O)C=C Chemical compound CN1CCC[C@H]1COC2=NC3=C(CN(C(C3)C4=C(C=CC=C4F)OC)C)C(=N2)N5CCN(CC5)C(=O)C=C MPFFDQYFXIXPOY-HSTJUUNISA-N 0.000 description 2
- ZYFXLPVKHYOHKG-UHFFFAOYSA-N CNC1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)C3=C(C=CC=C3F)O)F Chemical compound CNC1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)C3=C(C=CC=C3F)O)F ZYFXLPVKHYOHKG-UHFFFAOYSA-N 0.000 description 2
- XFMWDKSIFUFREN-JTQLQIEISA-N C[C@H]1CN(CCN1C(=O)C2=CC(=C(C=C2F)Br)F)C(=O)OC(C)(C)C Chemical compound C[C@H]1CN(CCN1C(=O)C2=CC(=C(C=C2F)Br)F)C(=O)OC(C)(C)C XFMWDKSIFUFREN-JTQLQIEISA-N 0.000 description 2
- QAXXFNQNCXCOHU-SFHVURJKSA-N C[C@H]1CN(CCN1C(=O)C2=CC(=C(C=C2N(C3=C(C=CN=C3C(C)C)C)C(=O)C[N+](=O)[O-])Br)F)C(=O)OC(C)(C)C Chemical compound C[C@H]1CN(CCN1C(=O)C2=CC(=C(C=C2N(C3=C(C=CN=C3C(C)C)C)C(=O)C[N+](=O)[O-])Br)F)C(=O)OC(C)(C)C QAXXFNQNCXCOHU-SFHVURJKSA-N 0.000 description 2
- KKPPFDCBGANPCO-KRWDZBQOSA-N C[C@H]1CN(CCN1C(=O)C2=CC(=C(C=C2NC3=C(C=CN=C3C(C)C)C)Br)F)C(=O)OC(C)(C)C Chemical compound C[C@H]1CN(CCN1C(=O)C2=CC(=C(C=C2NC3=C(C=CN=C3C(C)C)C)Br)F)C(=O)OC(C)(C)C KKPPFDCBGANPCO-KRWDZBQOSA-N 0.000 description 2
- UWTFEMOYRDOOLF-SFHVURJKSA-N C[C@H]1CN(CCN1C2=C(C(=C=O)N(C3=CC(=C(C=C32)F)Br)C4=C(C=CN=C4C(C)C)C)[N+](=O)[O-])C(=O)OC(C)(C)C Chemical compound C[C@H]1CN(CCN1C2=C(C(=C=O)N(C3=CC(=C(C=C32)F)Br)C4=C(C=CN=C4C(C)C)C)[N+](=O)[O-])C(=O)OC(C)(C)C UWTFEMOYRDOOLF-SFHVURJKSA-N 0.000 description 2
- ZCIAPOSLCDRYQY-FQEVSTJZSA-N C[C@H]1CN(CCN1C2=C3C(=NC=N3)N(C4=CC(=C(C=C42)F)C5=C(C=CC=C5F)O)C6=C(C=CN=C6C(C)C)C)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C2=C3C(=NC=N3)N(C4=CC(=C(C=C42)F)C5=C(C=CC=C5F)O)C6=C(C=CN=C6C(C)C)C)C(=O)C=C ZCIAPOSLCDRYQY-FQEVSTJZSA-N 0.000 description 2
- QOCLBSWHZOQPOH-FQEVSTJZSA-N C[C@H]1CN(CCN1C2=NC(=O)N(C3=C(C(=NC=C32)C4=C(C=CC5=C4C=NN5)C)F)C6=C(C=CN=C6C(C)C)C)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C2=NC(=O)N(C3=C(C(=NC=C32)C4=C(C=CC5=C4C=NN5)C)F)C6=C(C=CN=C6C(C)C)C)C(=O)C=C QOCLBSWHZOQPOH-FQEVSTJZSA-N 0.000 description 2
- WOFLENLDTKYEIO-GVNKFJBHSA-N C[C@H]1CN(CCN1C2=NC(=O)N(C3=C2CN(C(C3)C4=C(C=CC=C4F)O)C)C5=C(C=CC=C5C(C)C)C)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C2=NC(=O)N(C3=C2CN(C(C3)C4=C(C=CC=C4F)O)C)C5=C(C=CC=C5C(C)C)C)C(=O)C=C WOFLENLDTKYEIO-GVNKFJBHSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100029974 GTPase HRas Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 241000282373 Panthera pardus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000002785 azepinyl group Chemical group 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- GSJRUEBQWPLHSN-UHFFFAOYSA-N n-methylmethanamine;oxolane Chemical compound CNC.C1CCOC1 GSJRUEBQWPLHSN-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- RGHXWDVNBYKJQH-UHFFFAOYSA-N nitroacetic acid Chemical compound OC(=O)C[N+]([O-])=O RGHXWDVNBYKJQH-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- GCRNGPNGNJSZCC-UHFFFAOYSA-N tert-butyl 3-amino-3a,4,6,6a-tetrahydro-1h-pyrrolo[3,4-c]pyrazole-5-carboxylate Chemical compound N1N=C(N)C2CN(C(=O)OC(C)(C)C)CC21 GCRNGPNGNJSZCC-UHFFFAOYSA-N 0.000 description 2
- SRSGDDVCIMFHCR-UHFFFAOYSA-N tert-butyl 4-(1-hydroxyprop-2-enyl)-4-prop-2-enylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC=C)(CC1)C(O)C=C SRSGDDVCIMFHCR-UHFFFAOYSA-N 0.000 description 2
- MZQDMBLLRIEPTM-UHFFFAOYSA-N tert-butyl 4-formyl-4-prop-2-enylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC=C)(C=O)CC1 MZQDMBLLRIEPTM-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- NIATVAWOUGSVBF-UHFFFAOYSA-N (4-methyl-2-propan-2-ylpyridin-3-yl)boronic acid Chemical compound B(C1=C(C=CN=C1C(C)C)C)(O)O NIATVAWOUGSVBF-UHFFFAOYSA-N 0.000 description 1
- WLXFQWJYMRTINR-UHFFFAOYSA-N 1,2,3,4,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-6-one Chemical compound C1NCCN2C(=O)CCCC21 WLXFQWJYMRTINR-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- DQXNTSXKIUZJJS-UHFFFAOYSA-N 2,4-dichloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 1
- GDHHAOFBLGZCMI-UHFFFAOYSA-N 2,4-dichloro-6,7-dihydro-5h-cyclopenta[d]pyrimidine Chemical compound ClC1=NC(Cl)=NC2=C1CCC2 GDHHAOFBLGZCMI-UHFFFAOYSA-N 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JWDLEVZYUTZUBA-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;phosphono dihydrogen phosphate Chemical compound OP(O)(=O)OP(O)(O)=O.O=C1NC(N)=NC2=C1NC=N2 JWDLEVZYUTZUBA-UHFFFAOYSA-N 0.000 description 1
- SFRJQFICUQFDFU-UHFFFAOYSA-N 2-amino-4-bromo-3-fluorobenzoic acid Chemical compound NC1=C(F)C(Br)=CC=C1C(O)=O SFRJQFICUQFDFU-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- IQVYHPUXNYVYFW-UHFFFAOYSA-N 4,6-dichloropyridine-3-carboxamide Chemical compound NC(=O)C1=CN=C(Cl)C=C1Cl IQVYHPUXNYVYFW-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- XQYICHLOAMMXKE-UHFFFAOYSA-N 5-amino-2-fluorophenol Chemical compound NC1=CC=C(F)C(O)=C1 XQYICHLOAMMXKE-UHFFFAOYSA-N 0.000 description 1
- RRWAPFKBOJWJGU-UHFFFAOYSA-N 5-bromo-2,4-dichloro-6-methylpyrimidine Chemical compound CC1=NC(Cl)=NC(Cl)=C1Br RRWAPFKBOJWJGU-UHFFFAOYSA-N 0.000 description 1
- ZYULSOMUIVUDJA-UHFFFAOYSA-N 5-chloro-1-(oxan-2-yl)indazol-4-ol Chemical compound ClC1=C(C=2C=NN(C=2C=C1)C1OCCCC1)O ZYULSOMUIVUDJA-UHFFFAOYSA-N 0.000 description 1
- PSQJQWHWSUOOGM-UHFFFAOYSA-N 7-(2-fluoro-6-hydroxyphenyl)-6-methyl-4-(4-prop-2-enoylpiperazin-1-yl)-1,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-one Chemical compound CN1CC2=C(CC1C3=C(C=CC=C3F)O)NC(=O)N=C2N4CCN(CC4)C(=O)C=C PSQJQWHWSUOOGM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QDHUVOZIFRUUSS-UHFFFAOYSA-N 8-azaspiro[4.5]dec-2-en-4-one hydrochloride Chemical compound Cl.O=C1C=CCC11CCNCC1 QDHUVOZIFRUUSS-UHFFFAOYSA-N 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- ZKEGOLMEKDUUFR-UHFFFAOYSA-N C(=O)=C1C=CCC11CCN(CC1)C(=O)OC(C)(C)C Chemical compound C(=O)=C1C=CCC11CCN(CC1)C(=O)OC(C)(C)C ZKEGOLMEKDUUFR-UHFFFAOYSA-N 0.000 description 1
- XDHKJGNNZURWGX-UHFFFAOYSA-N C=C1CCC2CNCCN2C1=O Chemical compound C=C1CCC2CNCCN2C1=O XDHKJGNNZURWGX-UHFFFAOYSA-N 0.000 description 1
- GCASQNHCDJBBNK-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN2C(C1)CCC(=C)C2=C=O Chemical compound CC(C)(C)OC(=O)N1CCN2C(C1)CCC(=C)C2=C=O GCASQNHCDJBBNK-UHFFFAOYSA-N 0.000 description 1
- ZQDKFUKHXBTUSK-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCN2C(C1)CCCC2=C=O Chemical compound CC(C)(C)OC(=O)N1CCN2C(C1)CCCC2=C=O ZQDKFUKHXBTUSK-UHFFFAOYSA-N 0.000 description 1
- GKWRARDCAOSJHE-UHFFFAOYSA-N CC1=C(C(=NC=C1)C(C)C)N2C3=CC(=NC=C3C(=NC2=O)Cl)Cl Chemical compound CC1=C(C(=NC=C1)C(C)C)N2C3=CC(=NC=C3C(=NC2=O)Cl)Cl GKWRARDCAOSJHE-UHFFFAOYSA-N 0.000 description 1
- VZPGMEMPIDRYPJ-SFHVURJKSA-N CCC1=CC=C(C=C1)C(=O)NC2=C(C(=C(C=C2C(=O)N3CCN(C[C@@H]3C)C(=O)C=C)Cl)C4=C(C=CC=C4F)OC)F Chemical compound CCC1=CC=C(C=C1)C(=O)NC2=C(C(=C(C=C2C(=O)N3CCN(C[C@@H]3C)C(=O)C=C)Cl)C4=C(C=CC=C4F)OC)F VZPGMEMPIDRYPJ-SFHVURJKSA-N 0.000 description 1
- CAACSWHIWHAXTF-UHFFFAOYSA-N CN(C)C1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)C3=C(C=CC=C3F)OC)F Chemical compound CN(C)C1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)C3=C(C=CC=C3F)OC)F CAACSWHIWHAXTF-UHFFFAOYSA-N 0.000 description 1
- KAMXACOLMLNIOV-UHFFFAOYSA-N CN1CC2=C(CC1C3=C(C=CC=C3F)OC)N=C(N=C2N4CCN(CC4)C(=O)C=C)OC Chemical compound CN1CC2=C(CC1C3=C(C=CC=C3F)OC)N=C(N=C2N4CCN(CC4)C(=O)C=C)OC KAMXACOLMLNIOV-UHFFFAOYSA-N 0.000 description 1
- NFRMBSTZQMIAIR-UHFFFAOYSA-N CNC1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)C3=C(C=CC=C3F)OC)F Chemical compound CNC1=C(C(=C(C=C1C(=O)N2CCN(CC2)C(=O)C=C)Cl)C3=C(C=CC=C3F)OC)F NFRMBSTZQMIAIR-UHFFFAOYSA-N 0.000 description 1
- BJJGHYAWSRPLTI-XOUCVQQTSA-N C[C@@H](CN(CC1)C(C=C)=O)N1C(C1=CC(Cl)=C(C(C(OC)=CC=C2)=C2F)C(F)=C1/N=C/N(C)C)=O Chemical compound C[C@@H](CN(CC1)C(C=C)=O)N1C(C1=CC(Cl)=C(C(C(OC)=CC=C2)=C2F)C(F)=C1/N=C/N(C)C)=O BJJGHYAWSRPLTI-XOUCVQQTSA-N 0.000 description 1
- VYBRDLXBWABOPM-KRWDZBQOSA-N C[C@H]1CN(CCN1C(=O)C2=CC(=C(C(=C2NC(=O)C3=CC=C(C=C3)C(=O)NC)F)C4=C(C=CC=C4F)OC)Cl)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C(=O)C2=CC(=C(C(=C2NC(=O)C3=CC=C(C=C3)C(=O)NC)F)C4=C(C=CC=C4F)OC)Cl)C(=O)C=C VYBRDLXBWABOPM-KRWDZBQOSA-N 0.000 description 1
- BRIAWZWDYXQCOW-KRWDZBQOSA-N C[C@H]1CN(CCN1C(=O)C2=CC(=C(C(=C2NC(=O)C3=CC=CC(=C3)C#N)F)C4=C(C=CC=C4F)OC)Cl)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C(=O)C2=CC(=C(C(=C2NC(=O)C3=CC=CC(=C3)C#N)F)C4=C(C=CC=C4F)OC)Cl)C(=O)C=C BRIAWZWDYXQCOW-KRWDZBQOSA-N 0.000 description 1
- FAUVATKNQKWXNU-INIZCTEOSA-N C[C@H]1CN(CCN1C(=O)C2=CC(=C(C(=C2NC(=O)C3=CC=CC(=C3)C(=O)N)F)C4=C(C=CC=C4F)OC)Cl)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C(=O)C2=CC(=C(C(=C2NC(=O)C3=CC=CC(=C3)C(=O)N)F)C4=C(C=CC=C4F)OC)Cl)C(=O)C=C FAUVATKNQKWXNU-INIZCTEOSA-N 0.000 description 1
- HWVCBKJLJPVUMD-KRWDZBQOSA-N C[C@H]1CN(CCN1C2=C3C(=NC=N3)N(C4=CC(=C(C=C42)F)Br)C5=C(C=CN=C5C(C)C)C)C(=O)C=C Chemical compound C[C@H]1CN(CCN1C2=C3C(=NC=N3)N(C4=CC(=C(C=C42)F)Br)C5=C(C=CN=C5C(C)C)C)C(=O)C=C HWVCBKJLJPVUMD-KRWDZBQOSA-N 0.000 description 1
- RGUKQXKKYCNXIT-KRWDZBQOSA-N C[C@H]1CN(CCN1C2=NC(=C=O)N(C3=NC(=C(C=C23)F)Cl)C4=C(C=CN=C4C(C)C)C)C(=O)OC(C)(C)C Chemical compound C[C@H]1CN(CCN1C2=NC(=C=O)N(C3=NC(=C(C=C23)F)Cl)C4=C(C=CN=C4C(C)C)C)C(=O)OC(C)(C)C RGUKQXKKYCNXIT-KRWDZBQOSA-N 0.000 description 1
- ZKPINHXQIZBWMR-AWEZNQCLSA-N C[C@H]1CNCCN1C2=NC(=O)N(C3=CC(=NC=C32)Cl)C4=C(C=CN=C4C(C)C)C Chemical compound C[C@H]1CNCCN1C2=NC(=O)N(C3=CC(=NC=C32)Cl)C4=C(C=CN=C4C(C)C)C ZKPINHXQIZBWMR-AWEZNQCLSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101100379081 Emericella variicolor andC gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229940124785 KRAS inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- XIHYZZRVLQMHEO-VEDVMXKPSA-N O=C(OC)C1CN([C@@H](CN1)C)C(=O)OC(C)(C)C Chemical compound O=C(OC)C1CN([C@@H](CN1)C)C(=O)OC(C)(C)C XIHYZZRVLQMHEO-VEDVMXKPSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- KMKCJXPECJFQPQ-UHFFFAOYSA-L dichloro-[(2-propan-2-yloxyphenyl)methylidene]ruthenium;tricyclohexylphosphane Chemical compound CC(C)OC1=CC=CC=C1C=[Ru](Cl)Cl.C1CCCCC1P(C1CCCCC1)C1CCCCC1 KMKCJXPECJFQPQ-UHFFFAOYSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- IJMWREDHKRHWQI-UHFFFAOYSA-M magnesium;ethene;chloride Chemical compound [Mg+2].[Cl-].[CH-]=C IJMWREDHKRHWQI-UHFFFAOYSA-M 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- DQNQNLWKAGZNIT-UHFFFAOYSA-N methyl 2,6-dichloropyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC(Cl)=NC(Cl)=N1 DQNQNLWKAGZNIT-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- NIPZZXUFJPQHNH-UHFFFAOYSA-M pyrazine-2-carboxylate Chemical compound [O-]C(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-M 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- FFWJHVGUAKWTKW-UHFFFAOYSA-M pyridine-3-thiolate Chemical compound N1=CC=CC(=C1)[S-] FFWJHVGUAKWTKW-UHFFFAOYSA-M 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- VKRHTLMJQOPTHL-SFHVURJKSA-N tert-butyl (3S)-4-[6-bromo-7-fluoro-4-(4-methyl-2-propan-2-ylpyridin-3-yl)imidazo[4,5-b]quinolin-9-yl]-3-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(CCN1C2=C3C(=NC=N3)N(C4=CC(=C(C=C42)F)Br)C5=C(C=CN=C5C(C)C)C)C(=O)OC(C)(C)C VKRHTLMJQOPTHL-SFHVURJKSA-N 0.000 description 1
- WPGLRFGDZJSQGI-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N)C1 WPGLRFGDZJSQGI-UHFFFAOYSA-N 0.000 description 1
- JYUQEWCJWDGCRX-UHFFFAOYSA-N tert-butyl 4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)CC1 JYUQEWCJWDGCRX-UHFFFAOYSA-N 0.000 description 1
- LPQFKJWJZFGTOW-UHFFFAOYSA-N tert-butyl 4-prop-2-enoyl-4-prop-2-enylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC=C)(CC1)C(=O)C=C LPQFKJWJZFGTOW-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及芳香杂环类衍生物调节剂、其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为KRAS G12C突变抑制剂，在治疗白血病、神经母细胞瘤、黑色素瘤、乳腺癌、肺癌及其结肠癌等疾病或病症的用途，其中通式(I)中的各取代基与说明书中的定义相同。
Description
PCT国内申请，说明书已公开。
Claims (21)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910471133X | 2019-05-31 | ||
| CN201910471133 | 2019-05-31 | ||
| CN2019108561863 | 2019-09-10 | ||
| CN201910856186 | 2019-09-10 | ||
| CN2019108561878 | 2019-09-10 | ||
| CN201910856187.8A CN112552294B (zh) | 2019-09-10 | 2019-09-10 | 含哌嗪杂环类衍生物抑制剂、其制备方法和应用 |
| CN201910860731 | 2019-09-11 | ||
| CN2019108607316 | 2019-09-11 | ||
| CN2020100148451 | 2020-01-07 | ||
| CN202010014845 | 2020-01-07 | ||
| PCT/CN2020/093731 WO2020239123A1 (zh) | 2019-05-31 | 2020-06-01 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113396147A true CN113396147A (zh) | 2021-09-14 |
| CN113396147B CN113396147B (zh) | 2024-06-18 |
Family
ID=73553522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080012821.0A Active CN113396147B (zh) | 2019-05-31 | 2020-06-01 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113396147B (zh) |
| WO (1) | WO2020239123A1 (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113853373A (zh) * | 2019-10-30 | 2021-12-28 | 劲方医药科技(上海)有限公司 | 取代的杂环并环类化合物，其制法与医药上的用途 |
| CN114728968A (zh) * | 2019-09-20 | 2022-07-08 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| US11912723B2 (en) | 2022-02-09 | 2024-02-27 | Quanta Therapeutics, Inc. | KRAS modulators and uses thereof |
| CN114728968B (zh) * | 2019-09-20 | 2024-11-15 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3871673B1 (en) | 2018-10-26 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | Novel indazole compound or salt thereof |
| CN112300194B (zh) * | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类稠环吡啶酮类化合物、制备方法和用途 |
| BR112022007783A8 (pt) | 2019-10-28 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer |
| AU2020408562A1 (en) * | 2019-12-20 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| GB202001344D0 (en) * | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| AU2021233058B2 (en) * | 2020-03-12 | 2024-05-16 | D3 Bio(Wuxi) Co., Ltd | Pyrimidoheterocyclic compounds and application thereof |
| CN115335372B (zh) * | 2020-04-03 | 2024-01-12 | 南京明德新药研发有限公司 | 八氢吡嗪并二氮杂萘啶二酮类化生物 |
| WO2021248090A1 (en) * | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2022121839A1 (zh) * | 2020-12-08 | 2022-06-16 | 上海和誉生物医药科技有限公司 | 吡啶并[2,3-d]嘧啶-2(1H)-酮衍生物及其制备方法和应用 |
| WO2022133345A1 (en) * | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| TWI793999B (zh) * | 2021-02-01 | 2023-02-21 | 大陸商南京明德新藥研發有限公司 | 嘧啶並吡喃化合物 |
| KR20230157463A (ko) * | 2021-03-17 | 2023-11-16 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | 피리미딘-융합된 환형 화합물, 이의 제조 방법 및 이의 용도 |
| CN116964056A (zh) * | 2021-03-25 | 2023-10-27 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物盐型、晶型及其应用 |
| CN115124533A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法和其医药上的用途 |
| WO2022223037A1 (zh) * | 2021-04-22 | 2022-10-27 | 劲方医药科技(上海)有限公司 | Kras抑制剂的盐或多晶型物 |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| WO2022266069A1 (en) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Tricyclic kras g12d inhibitors |
| WO2022265974A1 (en) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Aminoheterocycle-substituted tricyclic kras inhibitors |
| WO2022266167A1 (en) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Amide and urea-containing tricyclic kras inhibitors |
| WO2022271658A1 (en) * | 2021-06-23 | 2022-12-29 | Erasca, Inc. | Tricyclic kras inhibitors |
| WO2023283933A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Biotech Co., Ltd. | Compounds useful as kras g12d inhibitors |
| WO2023001123A1 (zh) * | 2021-07-19 | 2023-01-26 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| KR20240087636A (ko) * | 2021-07-23 | 2024-06-19 | 수저우 잔롱 파마 리미티드 | Kras g12d 억제제 및 이의 용도 |
| EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| WO2023041059A1 (zh) * | 2021-09-18 | 2023-03-23 | 南京明德新药研发有限公司 | 八氢吡嗪并二氮杂萘啶二酮化合物及其晶型 |
| WO2023183755A1 (en) * | 2022-03-21 | 2023-09-28 | Erasca, Inc. | Tricyclic pyrimidones |
| WO2023212549A1 (en) * | 2022-04-26 | 2023-11-02 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| TW202400609A (zh) * | 2022-04-26 | 2024-01-01 | 美商伊瑞斯卡公司 | 三環吡啶酮及嘧啶酮 |
| WO2024031088A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024076674A1 (en) * | 2022-10-05 | 2024-04-11 | Amgen Inc. | Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104844573A (zh) * | 2015-04-17 | 2015-08-19 | 中国药科大学 | 嘧啶类btk抑制剂、其制备方法及医药用途 |
| CN105189456A (zh) * | 2013-03-15 | 2015-12-23 | 亚瑞克西斯制药公司 | Kras g12c的共价抑制剂 |
| WO2016044772A1 (en) * | 2014-09-18 | 2016-03-24 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190272A1 (ar) * | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US11090304B2 (en) * | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MA51848A (fr) * | 2018-06-12 | 2021-04-21 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
-
2020
- 2020-06-01 WO PCT/CN2020/093731 patent/WO2020239123A1/zh active Application Filing
- 2020-06-01 CN CN202080012821.0A patent/CN113396147B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105189456A (zh) * | 2013-03-15 | 2015-12-23 | 亚瑞克西斯制药公司 | Kras g12c的共价抑制剂 |
| WO2016044772A1 (en) * | 2014-09-18 | 2016-03-24 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| CN104844573A (zh) * | 2015-04-17 | 2015-08-19 | 中国药科大学 | 嘧啶类btk抑制剂、其制备方法及医药用途 |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114728968A (zh) * | 2019-09-20 | 2022-07-08 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| CN114728968B (zh) * | 2019-09-20 | 2024-11-15 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| CN113853373A (zh) * | 2019-10-30 | 2021-12-28 | 劲方医药科技(上海)有限公司 | 取代的杂环并环类化合物，其制法与医药上的用途 |
| CN115057872A (zh) * | 2019-10-30 | 2022-09-16 | 劲方医药科技(上海)有限公司 | 取代的杂环并环类化合物，其制法与医药上的用途 |
| US12054497B2 (en) | 2019-10-30 | 2024-08-06 | Genfleet Therapeutics (Shanghai)Inc. | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
| US11912723B2 (en) | 2022-02-09 | 2024-02-27 | Quanta Therapeutics, Inc. | KRAS modulators and uses thereof |
| US12145947B2 (en) | 2023-11-07 | 2024-11-19 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020239123A1 (zh) | 2020-12-03 |
| CN113396147B (zh) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113396147A (zh) | 芳香杂环类衍生物调节剂、其制备方法和应用 | |
| AU2022201413B2 (en) | Fused ring compounds | |
| CN112368283B (zh) | 含二并环类衍生物抑制剂、其制备方法和应用 | |
| EP4074713B1 (en) | 1'-(imidazo[1,2-c]pyrimidin-5-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4'-piperidine]-5-amine derivatives and related compounds as shp2 inhibitors for the treatment of cancer | |
| CN113166103B (zh) | Egfr抑制剂及其应用 | |
| CN112552294B (zh) | 含哌嗪杂环类衍生物抑制剂、其制备方法和应用 | |
| CN113423703A (zh) | 含氮杂环类衍生物调节剂、其制备方法和应用 | |
| WO2021143680A1 (zh) | 杂芳基类衍生物及其制备方法和用途 | |
| CN115353509A (zh) | 含氮杂芳类衍生物调节剂、其制备方法和应用 | |
| WO2022214053A1 (zh) | 泛素特异性蛋白酶1(usp1)抑制剂 | |
| CN114539245A (zh) | 含嘧啶并环类衍生物调节剂、其制备方法和应用 | |
| CN112079830A (zh) | 含并环类衍生物抑制剂、其制备方法和应用 | |
| WO2022161461A1 (zh) | Sos1抑制剂及其制备方法和应用 | |
| CN113061132A (zh) | 一类稠环内酰胺类化合物、制备方法和用途 | |
| WO2022012409A1 (zh) | 一种rock抑制剂及其制备方法和用途 | |
| CN112292378A (zh) | 含吲哚类衍生物抑制剂、其制备方法和应用 | |
| CN117062818A (zh) | 新型sos1抑制剂及其制备方法和应用 | |
| CN112574235A (zh) | 一种ret抑制剂、其药物组合物及其用途 | |
| KR20220140710A (ko) | 트리아졸로피리다진 유도체, 이의 제조 방법, 약물 조성물 및 용도 | |
| JP2023509155A (ja) | ビフェニル系誘導体阻害剤、その調製方法及び使用 | |
| CN113166141A (zh) | 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 | |
| WO2022033455A1 (zh) | 具有egfr抑制活性的三嗪衍生物及其制备方法和应用 | |
| WO2023041049A1 (zh) | 作为sos1抑制剂的杂环化合物及其用途 | |
| WO2022100738A1 (zh) | 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用 | |
| KR20240128831A (ko) | 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |